Cancer Vaccines

Allogeneic Tumor Cell Vaccine Attacks Colon Carcinoma

Published in Gene Therapy Weekly, July 6th, 2000

A CD80 gene modified allogeneic colon cancer vaccine has been developed by collaborating academic and industry researchers.

"We developed a practical allogeneic tumor cell vaccine for the immuno-gene therapy of colon cancer based on the immunologic profiles of established colon carcinoma cell lines compared to fresh colon carcinoma cultures," announced Daniel L. Shawler and colleagues from Sidney Kimmel Cancer Center and Immune Response Corporation, California. "The vaccine consists of three established cell lines, SW620, COLO 205, and SW403, that are HLA-A2 positive; do not secrete high levels of the immunosuppressive factors TGF-(beta)1 and -(beta)2, interleukin...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2000-07-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry